At the Global Advances in Urology Conference 2026 held at Kokilaben Dhirubhai Ambani Hospital, Mumbai, Dr Bhosale highlighted advances in perioperative immunotherapy in bladder cancer. Attended by over 100 urologists globally, the session focused on integrating immune checkpoint inhibitors in neoadjuvant and adjuvant settings. Key data included improved pathological response rates with neoadjuvant immunotherapy and evolving evidence for adjuvant use in high-risk patients post-cystectomy. Combination strategies with chemotherapy and ongoing trials were discussed. The talk emphasized a paradigm shift toward immunotherapy-driven perioperative management to improve long-term outcomes in muscle-invasive bladder cancer.
